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Interleukin-6 (IL-6) is a multifunctional cytokine with both pro- and anti-
inflammatory properties with a heritability estimate of up to 61%. The circulating 
levels of IL-6 in blood have been associated with an increased risk of complex disease 
pathogenesis. We conducted a two-staged, discovery, and replication meta genome-
wide association study (GWAS) of circulating serum IL-6 levels comprising up to 
67,428 (ndiscovery=52,654 and nreplication=14,774) individuals of European ancestry. The 
inverse variance fixed-effects based discovery meta-analysis, followed by replication 
led to the identification of two independent loci, IL1F10/IL1RN rs6734238 on 
Chromosome (Chr) 2q14, (pcombined= 1.8×10
-11



























) in the combined meta-analyses of all samples. We also 
replicated the IL6R rs4537545 locus on Chr1q21 (pcombined=1.2×10
-122
). 
Our study identifies novel loci for circulating IL-6 levels uncovering new 






























Interleukin-6 (IL-6) is a multifunctional cytokine, which is involved in a wide range 
of immunomodulatory processes, from cellular migration and adhesion to 
proliferation and maturation (1, 2). Interleukins are involved in immune cell 
differentiation and activation (3). IL-6 is synthesized by a variety of different immune 
cells such as monocytes (4), B-cells (5) and T-cells (6) and also non-immune cells 
such as epithelial and smooth muscle cells (7), adipocytes (8), endothelial cells (9), 
and osteoblasts (10). 
Several factors have been implicated in circulating IL-6 levels. We have 
previously demonstrated that IL-6 levels decrease with age in children and increase 
with age in adults (11). Also, increased levels of IL-6 have been observed in various 
diseases, not surprisingly in autoimmune diseases such as rheumatoid arthritis (12) 
and systemic juvenile idiopathic arthritis (13), but also cardio-metabolic diseases like 
type 2 diabetes (14), heart failure, coronary heart disease (15), and atherosclerosis 
(16), as well in cancers (17), atopic dermatitis (18), and psychological disorders like 
depression (19). Due to its implications in the pathogenesis of different disorders, Il-6 
has been used as an appropriate choice for drug targeting and used as a monitoring 
biomarker of disease progression and response to treatments (20). The most illustrious 
IL-6 inhibitor is tocilizumab (21), a monoclonal antibody binding the IL-6 receptor, 
which is already in use for treating patients with allergic asthma (22), and immune 
system disorders like rheumatoid arthritis (23) and systemic juvenile idiopathic 
arthritis (24), with high efficacy with some initial benefits towards respiratory 
illnesses like COVID-19 (25). 
IL-6 baseline levels are heritable with estimates from twin studies ranging 

























with levels of IL-6 constituted relatively small-scale GWAS (30-33) or sequencing-
based candidate gene association studies (34). To date, variants in the IL-6 receptor 
gene (IL-6R) and the gene encoding histo-blood group ABO system transferase (ABO) 
have been identified as statistically significant for an association to IL6-levels. Also, 
the genetic risk score constructed of IL-6 variants identified in the study by Shah and 
colleagues explained up to 2% of the variation in IL-6 levels (33), leaving a 
substantial part of its heritability unexplained. These seemingly sparse results and 
limited findings could be due to limitations in the study power caused by low sample 
size or a great inter-individual variability of IL-6 levels. One may speculate a 
substantial increase in the study size by increasing the number of participants, which 
would very likely lead to the identification of additional variants explaining IL-6 
levels (35-37). 
The current study is the (till date) largest meta GWAS study including 67,428 
individuals of European ancestry to identify genetic variants explaining the levels of 
circulating IL-6 and to understand underlying genetic mechanisms implicated in the 




























A total of 52,654 individuals of European descent from 26 cohorts were included in 
the discovery GWAS meta-analysis with up to 2,454,025 autosomal SNPs passing 
quality control. Four cohorts (ALSPAC, MONICA/KORA, NTR, and SardiNIA), 
identified genome-wide significant associations in the ABO region, whereas none of 
the other 22 cohorts did, either individually or combined. These cohorts conditioned 
their results on their relevant top-SNP in ABO, the results of which were included in 
the discovery meta-analyses. The overall genomic control inflation factor (λGC after 
correction) at the discovery stage meta-analysis was 1.0.  
 We identified 94 variants that were genome-wide significantly (pdiscovery < 
5.0×10
−8
; Supplementary table 1) associated with IL-6 levels, representing two 
independent genetic loci on chromosomes 1q21 and 6p21. Two common SNPs 
(rs4537545 and rs660895), one per locus, Chr. 1q21 (IL6R), and Chr. 6p21 (HLA-
DRB1/HLA-DRB5), showed the most significant association with IL-6 levels (index 
SNPs) and the third SNP (rs6734238) mapped on Chr. 2q14 (IL1F10/IL1RN) locus 
showed suggestive (5.0×10
−8
 <  pdiscovery < 1.0×10
−5
) association in addition to 5 other 
loci (LHFPL3, LZTS1, GPC5/GPC6, USP32/APPBP2, STAU1; Supplementary table 
2).  
The minor alleles of IL6R rs4537545*T (β=0.091; pdiscovery =8.39×10
-85
), 
IL1F10/IL1RN rs6734238*G (β=0.025; pdiscovery =1.45×10
-7
) and HLA-DRB1/5 
rs660895*G (β=0.036; pdiscovery=1.80×10
-9
) associated with increased circulating IL-6 
levels (Table 1). Two additional genome-wide significant SNPs in the IL1R locus,  
rs11265618 (β=0.047; pdiscovery=1.21×10
-15
) and rs10796927 (β=0.034; 
pdiscovery=1.24×10
-11
), in low LD (r
2

























forward for replication, and later conditional analysis as they seemed potential 
candidates as independent signals.  
 Overall, 12 SNPs spanning over 9 loci, at a pdiscovery<1×10
−5
 in the discovery 
GWAS meta-analyses were selected for the replication stage (Supplementary table 2). 
This included the three index SNPs, two additional SNPs from the 1q21 locus (GWS 
but in low LD, r
2
<0.25 with index SNP) plus an additional set of seven statistically 




 in the discovery meta-analyses 
(either in low LD, r
2
<0.25 with the index SNP or independent loci). Additionally, 3 
SNPs as negative controls and 3 SNPs in LD (r
2
>0.25) with the Chr. 1 index SNP, to 
control for possible genotyping errors of index SNP across replication cohorts, were 
also added to the replication list, yielding 18 SNPs for replication stage 
(Supplementary Table 3).  
Three loci including Chr.1q21 IL6R, Chr.6p21 HLA-DRB1/5 and Chr.2q14 
ILF10/IL1RN replicated at preplication<0.05, reaching GWS; 1q21 rs4537545, 
pcombined=1.20×10
−122
; 6p21 rs660895, pcombined=1.55×10
−10
; and 2q14 rs6734238, 
pcombined= 1.84×10
−11
 in the combined meta-analyses (Table 1; Supplementary table 
3). The two additional signals at Chr.1q21 IL6R locus were replicated at preplication= 
1.7×10
−4





, respectively (Supplementary Table 3). The conditional analysis, 
confirmed that rs11265618 and rs10796927 SNPs were not independent from 
(Supplementary table 4) but were driven by the index rs4537545 SNP.  
In both, discovery and replication association analyses, the effect 
directionality was generally consistent across individual studies for GWS variants, 
while there was some evidence of borderline heterogeneity in one of the two novel 



























The imputation quality scores (r
2
) for the GWS (index) SNPs for each cohort 
(discovery and replication) are available in Supplementary table 5. The other seven 
SNPs that showed suggestive association in the discovery stage, and expectedly the 
negative control SNPs did not reach GWS in the combined meta-analyses 
(Supplementary table 3). 
The three GWAS index SNPs when combined, explained approximately 1.06% of the 
variance in circulating levels of IL-6 using data from the NESDA cohort. The 
phenotypic variance explained by all the common variants was estimated to be 4.45% 
using the SumVg method (38). 
Replication of other known/suggestive loci for IL-6  
IL6R was the only IL6 known locus that we replicate at GWS. IL1RN and HLA-





) by Shah et al. while some known/suggestive IL6 loci (ABO, BUD13, TRIB3, and 
SEZ6L) did not replicate (pdiscovery>0.05) in the current study. 
SNP functionality 
We looked up SNPs in LD with the index SNPs from the immunologically associated 
loci including IL-6R, rs4537545, 1q21; IL1F10, IL1RN, rs6734238, 2q14, intergenic; 
and HLA-DRB1/DRB5, rs660895, 6p21, intergenic. The search for 
functional/missense variants in high LD (r
2
>0.8) with the lead SNPs led to the 
identification of only one nonsynonymous rs2228145 SNP in LD (r
2
=0.95) with the 
rs4537545 index SNP from the IL6R locus. We used the Combined Annotation-
Dependent Depletion (CADD) database to identify the functionality,  ie. deleterious, 
disease causal, pathogenicity, of rs2228145 in IL6R. CADD is an integrative 

























missensethe  rs2228145 variant has a CADD score of 15.98 
(https://cadd.gs.washington.edu).   
Associations with other traits and gene expression data  
Genome-wide significant associations between IL6 associated top SNPs and other 
traits, and gene expression, data were mined using the Pheno Scanner v2 database 
(accessed, October 2020).  
GWAS based IL1F10/IL1RN rs6734238*G allele has been associated with increased 
levels of serum C reactive protein (CRP) and decreased fibrinogen levels, and blood 
cell traits in recent GWAS reports (40, 41) (PMID:27863252; Supplementary table 6).   
HLA-DRB1/DRB5 rs660895*G allele is associated with increased risk of Rheumatoid 
arthritis (RA) in Europeans and Asians (42), IgA nephropathy in Asians (43), while 
the decreased risk of Ulcerative colitis and Inflammatory Bowel Disease (IBD) (44). 
IL-6R rs4537545*T allele has been associate with increased circulating CRP levels 
(45), a decreased risk of RA (42) in mixed ancestries, while an increased risk of 
diabetes and asthma from the UK Biobank Neale’s lab rapid GWAS (See Web 
Resources; Supplementary table 6). IL6R rs4537545T* allele is also associated with C 
reactive protein, allergic disease, rheumatoid arthritis, and coronary artery disease 
(Supplementary table 6). 
Gene expression: IL1F10/IL1RN rs6734238 is associated with IL1F10/IL1RN 
expression levels in the skin, peripheral blood, and whole blood (p<5.0×10
-8
; 
Supplementary table 7). HLA-DRB1/DRB5 rs660895 has been associated with HLA-
DRB1/DRB5/DRB6/DQB1/DQB2 expression levels in multiple tissues including 
peripheral blood, whole blood, monocytes, adipose tissue, thyroid, tibial artery, 
coronary artery, heart, lung, brain, colon, skeletal muscle, tibial nerve, skin, and, 
lymphoblastoid cell lines (p<5.0×10
-8



























is also associated with IL6R expression levels in peripheral and whole blood 
(p<5.0×10
-8
; Supplementary table 7).  
Power estimates 
Based on power calculator and assumptions mentioned under methods section, the 
estimated power for the 2 novel index SNPs was 98.3% rs6734238 (Effect allele 
frequency, EAF: 0.42), and 76.9% rs660895 (EAF: 0.19), respectively. 
 
DISCUSSION 
We performed the largest (to date) GWAS meta-analysis for circulating IL-6 levels, 
which includes 66,341 individuals of European ancestry. We identified three loci 
associated with levels of circulating of IL-6 in the general population amongst which 
two are novel (Chr6p21, and Chr2q14), located in/nearby genes (HLA-DRB1 and 
IL1RN/IL-38) with inflammatory roles explaining up to 1.06 % variance.  
The strongest associated SNP, interleukin-6 Receptor (IL-6R) rs4537545 at the 
1q21 locus, is in high LD (r
2
=0.95) with a missense IL-6R SNP rs2228145 (D358A) 
that results in an amino acid substitution at position 358 (Asp→Ala) on the 
extracellular domain of IL-6R and a high CADD score suggesting that the variant is 
pathogenic or functional or deleterious (among top 10% variants of the genome). The 
missense SNP is known to impair the responsiveness of cells targeted by IL-6 (46) by 
reducing IL-6R expression on cell surfaces (47), and increasing levels of soluble IL-
6R in individuals homozygous for this mutation (48, 49). Recently it has been 
demonstrated that increased levels of sIL-6R induced by this variant, can be explained 
by ectodomain shedding off IL-6R, a mechanism in which membrane-associated 
proteins are rapidly converted into soluble effectors whereby simultaneously cell 
surface expression of the same protein is reduced (50). Increased levels of sIL-6R 

























protective effect of the 358A allele for various cardiovascular diseases including 
coronary artery disease (CAD) (51-53), atrial fibrillation (54), lung function in 
asthmatics (55), and abdominal aortic aneurysm (56) as well as RA (57). However in 
contrast with this finding, the IL-6-sIL-6R complex itself is capable of transducing 
IL-6 signaling to non-IL-6R expressing cells, known as trans-signaling (58), and it is 
this mechanism, as opposed to classic signaling, that is linked to chronic 
inflammatory disorders including IBD and RA (59). Blocking IL-6 signaling cascades 
can be achieved by using an IL-6R specific inhibitor in the form of a monoclonal 
antibody, tocilizumab, which is a widely used therapy in the treatment of RA. Several 
variants in IL-6R, including rs2228145, may assist in the prediction of patient 
response to tocilizumab in RA (60). The rs4537545*T allele which is associated with 
IL6 levels is known to associate with increased circulating CRP levels (61)  and a 
decreased risk of RA (42) in studies comprising mixed ancestries. Moreover, this SNP 
has been associated with IL6R expression in peripheral blood, skin, brain, and adipose 
tissue (Supplementary table 7). The causal involvement of IL-6 levels in disease 
remains to be elucidated, but a recent study using a Mendelian randomisation (MR) 
approach did demonstrate that by using this SNP as instrumental variable, modelling 
the effects of tocilizumab, that IL-6R signalling has a causal effect on CAD (52). On 
the other hand, pleiotropic nature of the IL-6R locus, influencing IL-6, CRP, and 
fibrinogen levels, prohibits instrumental variable analysis and attribution of causality 
to one particular intermediate. Finally, several other genes encompass the 1q21 locus, 
including Src Homology 2 Domain Containing E (SHE), and Tudor Domain 
containing 10 (TDRD10), but have been ruled out to play a role at this locus (33).  
At the identified chromosome 2 locus the lead SNP, rs6734238, is intergenic 



























The nearest genes to this locus are the Interleukin 1 Family Member 10 (IL1F10, 
distance=7.6 kB, currently known as IL-38) and Interleukin 1 Receptor Antagonist 
(IL1RN, distance=34.4 kB). IL1F10/IL-38 and IL1RN variants (rs6759676 and 
rs4251961) in partial LD with the lead SNP (r
2
LD:0.10 and 0.61) have been recently 
reported to be protective against the development of insulin resistance (63). This 
further supports the molecular mechanisms behind IL-6 mediated insulin secretion via 
glucagon-like peptide 1 (GLP-1) (64) contributing to type 2 diabetes (T2D) 
pathophysiology. For IL-6 specifically, it has been found that synthesis increases 
when dendritic cells are stimulated by bacterial lipopolysaccharides (LPS) in the 
presence of IL1F10 (65). IL-1RN is another member of the interleukin 1 cytokine 
family, with suggestive evidence for involvement in determining IL-6 levels in the 
blood. One study found significant associations of IL-1RN rs4251961 with plasma 
CRP and IL-6 levels, albeit not independently replicated and not genome-wide 
significant (p=1×10
-4
 and p=0.004) (66). Our lead SNP was not in high LD (r
2 
<0.8) 
with variants in either neighboring genes and therefore in conjunction with its 
intergenic position, identifying a causal variant in this locus remains non-trivial. 
The 6p21 rs660895, which was identified, resides within the HLA region, 
which forms one of the most complex genomic regions to study due to its large LD 
blocks and sequence diversity. This region has some population substructure in 
Europeans which may have influenced the results however 1) each cohort population 
substructure adjustment was applied, followed by genomic correction for overall 
discovery stage meta-analyses. Thus, we reduced the chances that the population 
substructure may have had on this locus. The nearest genes to the index SNP, HLA-
DRB1 (distance=19.8 kB), and HLA-DQA1 (distance=27.8 kB) are both 

























for certain immune system cells helping in antigen presentation to trigger an immune 
response. It is noteworthy that variations at this locus code for antigen-presenting 
complexes (APCs) which have been previously associated with diseases having a 
dysfunctional immune system; while we report for the first time that there exists also 
a strong association of this locus with circulating cytokine levels. Therefore, the 
association of this locus with the disease may corroborate through its effect through 
IL6 levels. One high-LD SNP (rs9272422, r
2
=0.82 with our index SNP, rs660895) 
residing in the promoter region of HLA-DQA1, support this hypothesis and has been 
identified previously for Systemic Lupus Erythematosus (67) and Ulcerative Colitis 
(68). rs660895*G allele is associated with increased risk of RA in Europeans and 
Asians (42), IgA nephropathy in Asians (43), while the decreased risk of Ulcerative 
colitis and IBD. (44) 
Various studies aimed to identify genetic variation underlying levels of IL-6 
(22-26) have found genome-wide significant associations in the IL-6R and ABO 
genes. The study performed by Shah and colleagues
 
(33) found suggestive evidence 
(non-GWS; p=3.8×10
-6
 respectively) for additional loci, including ABO, BUD13, 
TRIB3, and SEZ6L, none of which replicate in the current study (pdiscovery>0.05) 
indicating that these might be false-positive findings due to low sample size (~7800) 
or loci with sex-specific effects (associations based on women dominant population) 
or due to technical shortcomings with measurement assay (ABO locus).  
It is surprising that even with increased statistical power (ndiscovery=52,654; 
nreplicaiton=14,774) in the current study (compared to the previous IL6 GWAS) (33), we 
could identify three genetic loci (1q21, 2q14, and 6p21) accounting for ~ 1% of the 
genetic variance for circulating IL-6 levels. According to the current estimates, the 



























enormous increase in sample sizes would be required to identify additional variants 
explaining this remaining heritability. Multiple explanations for this so-called missing 
heritability phenomenon have been proposed in the past, which can be sought in rare 
or low frequency coding variants as observed for a similar metabolic quantitative trait 
by us (69) or can be explained by non-additive effects which may cause inflated 
estimates of heritability. Plausible evidence for other sources of unexplained 
heritability that have been found are epigenetic changes, and haplotypes of common 
SNPs.  
Collectively, our results provided additional insights into the biology of 
circulating IL-6. We identify new loci, limited by common variants in the Hap Map 
Reference panel. Albeit this is comparable to the 1000 genomes reference panel (70) 
but narrower compared to some newly available panels that show greater variant 
coverage in numbers and frequency range. Future studies are recommended to aim for 
identification of additional common but also rare variants, by firstly using richer 
imputation panels, such as UK10K project or the Haplotype Reference Consortium, a 
strategy that holds great promise, and secondly by making use of genetically isolated 
populations. Thirdly, we would like to stress the importance of phenotype 
harmonization. As we identified genome-wide variants in the ABO locus, in four 
studies participating in the discovery, but not in the remaining 22 cohorts, there is a 
strong indication that this locus may be assay-specific. However, a proper 
demonstration of this hypothesis would require further testing, including repeating the 
GWAS in ABO positive cohorts using a different IL-6 assay. Indeed it is emerging 
that the ABO locus has pleiotropic effects on many different traits and diseases (71), 
which would suggest a more thorough analysis before disregarding this signal. Also, 

























substructures may raise heterogeneity within populations (72), likely concealing the 
SNPs that affect particular subgroups. Future specific studies should counter the 
widely held assumption of unconditional risk alleles of complex traits and focus on 
the importance of studying more homogenous subgroups to, for example, investigate 
the age-dependent effect of genetic variants (73, 74). Here while further exploring the 
pleiotropic effect of IL-6-related variants, we identified phenotypes differentially 
regulated by diverse variants in the 1q21 locus. Biologic systems are dynamic 
complex networks and are evolving through lifespan and investigating the 
interrelationships existing between phenotypes as well as between genetic variations 
and phenotypic variations has the potential for uncovering the complex mechanisms. 
This is the case here for IL-6 and tailored methodologies should be devoted to the 
study of such traits, hopefully resulting in clinically significant breakthroughs. Future 
collaborative efforts therefore should strive to use well-calibrated assays, z-
standardized protocols for sample handling, and processing
75
, though this will be 
difficult to achieve in practice. Lastly, we have attempted to perform formal 
association based causal analysis to identify the likely causal loci, using the DEPICT 
approach; unfortunately, instead with only 2 novel GWS findings, our analyses were 
underpowered and thus not included. We also mine the gene expression and eQTL 
data for the identified SNPs using established databases, however we were unable 
control for random co-localization signals or other confounders as we had limited 
access to summary level data. In conclusion, we identify two novel common genetic 
variants associated with circulating IL-6 levels that may influence the 
pathophysiology of complex cardio-metabolic, psychiatric and immunological traits, 
among individuals of European ancestry. This is a step further towards unravelling 



























the IL-6 related disorders, while suggesting looking deeper into the genome for 

























MATERIAL AND METHODS 
Discovery Stage 
Study populations  
The overall study design (Supplementary figure 1) involved the discovery cohorts 
with 53,893 individuals. After overlapping individuals with available genotype and 
phenotype data, the discovery stage included 52,654 individuals from 26 cohorts of 
European ancestry listed under Supplementary table 8, described in Supplementary 
text S1 and, study summary characteristics in Supplementary table 9. Only 
population-based samples or healthy controls from case-control studies were included 
in the final analyses.  
Serum IL-6 measurements  
Each study typically collected venous blood samples stored below -80°C until the 
time of measurement using various types of immunoassays and expressed as pg/ml as 
presented in Supplementary table 10. The trait transformation and phenotype data 
quality control (QC) were presented by Supplementary text S3.  (Supplementary text 
S3.1 and S3.2). In brief, participating cohorts have checked for the percentage of 
missingness in IL6 measurements and evaluated for indices of QC (Supplementary 
text S3.2), yielded the final number of participants with available validated IL6 levels, 
of whom those with available genotype data were included in the study as 
characterized in Supplementary table 9 and in Supplementary text S1 and S2. 
Genotyping and imputation  
Each participating cohort performed genome-wide genotyping using a variety of 
genotyping platforms, and applied a predefined quality control (QC) of genotype data 
(Supplementary table 11) followed by performing imputation of non-genotyped 



























reference panel (NCBI Build 36), and using statistical software such as IMPUTE (75), 
MACH, Minimac (76), or BIMBAM (77) (Supplementary table 11). Each cohort was 
recommended a set of general SNP quality filters including MAF<0.01; Hardy 
Wienberg Equilibrium (HWE) p<=10
-6
; imputation quality r
2 
≤ 0.3; and genotyping 
call rate<0.95 (Supplementary figure 1). Once we received summary results from 
each participating study, we ran a series of QC checks. Firstly these included a set 
standard checks, including the imputation quality filters (basis the imputation program 
used and/or r
2
imputation<0.3 were excluded), and then checks for genomic inflation 
(quantile-quantile or QQ plots). We adapted filter thresholds per cohort to reduce any 
observed deviation from the null while missing SNP loss due to the QC process. 




Each study conducted an independent GWAS analysis between SNPs and natural log-
transformed values of serum IL-6 levels following a predefined analysis plan 
(Supplementary methods S4). Association analyses were conducted using linear 
regression model, or linear mixed effect models to account for familial correlation 
when warranted, with additive genetic effects, accounting for imputation uncertainty 
while adjusting for age, sex, population sub-structure (through study-specific 
principal components), and/or study-specific site, when necessary. GWAS summary 
result obtained from each cohort underwent a series of QC checks using the 
QCGWAS package in R (78) (Supplementary text S3 and Supplementary figure 1). 
Being aware of the potential false-positive association in the ABO region on 

























measure IL6 levels (R&D systems, Minneapolis, MN, USA), four (out of 22) 
discovery cohorts that observed genome-wide significant results in the ABO locus, 
were asked to rerun the GWAS analysis conditional on the top ABO SNP (ie. 
rs8176704) before including them in the final discovery meta-analysis 
(Supplementary text S3.3).  
 
Discovery GWAS meta-analyses  
Individual GWAS results from 26 European studies were meta-analyzed using the 
inverse variance weighted, fixed-effects method as implemented in GWAMA while 
applying the double genomic control (GC) correction for population stratification i.e. 
first to each study individually and subsequently also to the pooled results after meta-
analysis(79).  
 Regional association plots for the discovered loci were generated through the 
LocusZoom (78) tool. We used the SNAP tool (80) to perform the pairwise LD 
checks (HapMap release 22 data) and to verify low LD with secondary signals. All 
SNPs selected for the replication stage had to fulfill the following criteria: (i) having 




being in very low LD with the index SNP 
(r
2
<0.2), and (ii) available in at least 50% of study cohorts.  
 
Replication and Combined Meta-analysis 
Study population, phenotyping and QC  
The overall study (Supplementary figure 1) comprised 15,785 individuals for 
replication. After removing individuals with missing data, the replication analyses 
were performed using a combination of in silico and de novo genotyping in 14,774 



























S2. Similar QC (Supplementary text S3, and Supplementary table 11) and statistical 
checks were made as in the discovery stage.  
Venous blood samples (serum or plasma) were collected and stored at -80°C. 
Serum/plasma IL-6 levels (pg/ml) were measured using various immunoassay 
methods described in Supplementary table 10. Each cohort tested the selected SNPs 
using the same statistical model as for the discovery association analyses 
(Supplementary figure 1). Effect size estimates of all replication SNPs from each 
replication study were compared with the effect size estimates from the discovery 
meta-analyses. When effect sizes from individual cohorts did not align, we excluded 
these cohorts from the replication meta-analyses (ncohorts=3). To account for the inter-
study assay differences insensitivity, we combined results across the replication 
studies using a fixed effect sample-size weighted Z-score meta-analysis as 
implemented in the METAL package (https://genome.sph.umich.edu/wiki/METAL) 
(81).  
 The summary GWAS meta-analyses result from the discovery and replication 
stages were then used to perform a combined (discovery + replication) GWAS meta-
analysis using a sample-size weighted Z-score method. Test for heterogeneity was 
also performed as part of the meta-analysis package using METAL where I
2 
statistic 
denoting the percentage of variation across studies was estimated (I
2
 = 100% × (Q-
df)/Q) where Q is the Chi-Square statistic. Significance for heterogeneity was denoted 
by the heterogeneity (or Hetp) p values. . Variants that were significant in the 
replication meta-analysis at p<0.05 and had an overall pcombined <5×10
-8
 in the 
combined meta-analysis were considered statistically GWS. SNPs within the range of 
1 Mb (or 10
6



























>0.25) were considered part of the same locus whereas those in low LD (r
2
<0.25) 
were tested if they were independent using conditional analysis.  
Conditional analysis 
 
We performed an approximate joint conditional analysis to identify distinct signals in 
a specific chromosomal region as implemented in GCTA (82) using high quality 
genome-wide genotyped/imputed reference data from two studies (NEtherlands Study 
of Depression and Anxiety (NESDA) from the Netherlands and/or Genetics of 
Obesity in Young Adults (GOYA) from Denmark) to estimate linkage disequilibrium 
(LD) (83) between SNPs.  
Conditional analysis  for identification of independent signals was performed 
on GWS SNPs (+/- 1 Mb to the index SNP and having low LD, r
2
<0.2 with the index 
SNP) using summary statistics from the discovery GWAS meta-analysis data (--
COJO option in GCTA) after confirming the GWS loci from the combined meta-
analysis.  
 
Heritability estimates  
We approximated the variance explained by all distinct lead SNPs from the meta-
analysis using the following formula: 
∑
βi





where EAF is the effect allele frequency, and 𝛽𝑖 the effect size of the individual 
variants and n is the total number of lead variants. The current formula may 
overestimate the variance to a small extent as some level of SNP correlation was 
existent (LD r
2
<0.25). The variance of the residuals of ln(IL-6) was calculated using 



























IL-6 levels explained by all GWAS variants was estimated using the observed Z-
statistics from the discovery analyses for a subset of pruned SNPs. Following the 
original method (SumVg) (38), we pruned the imputed (based on the 1000G Phase1 
Integrated Release, Version 3, 2012.04.30 reference panel) genotypes of the NESDA 
cohort using PLINK v1.07 (84), by removing correlated SNPs at r
2
>0.25 within a 
100-SNP sliding window, and with a step size of 25 SNPs per forwarding slide. This 
resulted in a pruned set of 163,459 SNPs. 
SNP mapping and functionality 
We searched for variants in high LD (r
2
>0.8) within a 1 Mb region on either side of 
the lead SNPs using 1000 Genomes sequence data (Phase1 Integrated Release, 
Version 3, 2012.04.30), utilizing tools available in Liftover (85), VCFtools (86), and 
clumping in PLINK (84). We subsequently annotated these variants using 
ANNOVAR (87) with the RefSeq (88) database for variant function and genic 
residence or distance. We used the Combined Annotation-Dependent Depletion 
(CADD) database to identify the functionality,  ie. deleterious, disease causal, 
pathogenicity, for the index SNPs. 
Associations with other traits and gene expression data 
PhenoScanner v2 (89) data mining tool was used (Access date October 2020) to 
identify existing GWS (at p<5×10
-8
) associations between IL6 identified SNPs and 
other traits, and gene expression/eQTLs data.  
Power calculation 
We used GWAs power estimator (see Web Resources) by assuming a relative risk of 
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Figure 1.  
Manhattan, QQ and LocusZoom plots of the discovery GWAS meta-analyses. 
A) Manhattan plot showing the association of SNPs with IL-6. Loci coloured in red or blue, 
three in total, represent those for which the lead SNPs reached genome-wide significance 
(P=5×10
−8
). Horizontal axis: relative genomic position of variants on the genome, vertical 
axis : -log10 p-value of each SNP; B) Quantile-quantile plot for p-values obtained from the  
meta-analysis. The horizontal and vertical axes represents the expected distribution of -log10 
(P-values) under the null hypothesis of no association, whereas the vertical axis shows the 
observed -log10 (P-values). The blue dashed line represents the null, and λgc value represents 
the genomic inflation factor lambda. Each data point represents the observed versus the 
expected p-value of a variant included in the association analyses; C-E) Regional association 
plots for each of the three genome-wide significant loci, 1q21, 2q14, and 6p21, respectively. 
Pairwise LD (r
2
) with the lead SNP is indicated following a color-coded scale. Horizontal 















































































Figure 2. Combined discovery and replication forrest plots for the GWAS Index SNPs. 
Forrest plots for A) IL6R rs4537545 (chr. 1q21), B) IL1RN rs6734238 (chr. 2q14) , C) HLA-
DRB5 rs660895 (chr. 6p21) with discovery, replication and combined effect estimates, 




























Table 1: Novel and replicated loci associated with circulating IL-6 levels at p < 
5.0 × 10
-8 






















Novel Loci  


























Replicated Known Locus  












 intronic IL6R < 0.01 (72) 
Index SNPs that reached p < 5×10−8 in the combined analysis from each locus are reported here. Sample sizes: discovery cohorts, 
n=52,654; replication cohorts, n=14,774; combined, n=67,428. The effect sizes (β) in the discovery phase, given for the effect allele. 
EAF: Effect Allele Frequency; Effect sizes and standard error (SE) values are based on natural log transformed IL6 (pg /ml) levels.  Phet: 
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